Moderator: Lisa A. Ferrara, PhD
111. Is osteoporosis screening routinely needed to evaluate cervical total disc replacement patients?
Scott L. Blumenthal, MD1; Richard D. Guyer, MD2; Jack E. Zigler, MD1; Donna D. Ohnmeiss, PhD3
1Texas Back Institute, Plano, TX, US; 2Center for Disc Replacement at Texas Back Institute, Plano, TX, US; 3Plano, TX, US
FDA Device/Drug Status: This abstract does not discuss or include any applicable devices or drugs.
112. Changes in flexion/extension range of motion due to oversizing of cervical total disc arthroplasty
Kee D. Kim, MD1; Tejas Karnati, MD2; Vijay N. Permeswaran, PhD3; Anup Gandhi, PhD4
1UC Davis School of Medicine, Sacramento, CA, US; 2UC Davis, Sacramento, CA, US; 3Zimmer Biomet Spine, Westminster, CO, US; 4Zimmer Biomet, Westminster, CO, US
FDA Device/Drug Status: This abstract does not discuss or include any applicable devices or drugs.
113. Segmental contribution to total cervical flexion-extension motion before and after cervical disc arthroplasty (CDA) – influence of prosthesis design
Avinash G. Patwardhan, PhD1; Robert M. Havey, MS2; Saeed Khayatzadeh, PhD3
1Loyola University Medical Center Dept. of Orthopaedic Surgery, Maywood, IL, US; 2Edward Hines Jr. VA Hospital, Hines, IL, US; 3Orthopedic Biomechanics Lab, Hines, IL, US
FDA Device/Drug Status: Mobi C Cervical disc prosthesis (Approved for this indication), M6 C Cervical disc prosthesis (Investigational/Not approved)
114. Intra-operative conversion of cervical total disc replacement to fusion: incidence and reasons
Scott L. Blumenthal, MD1; Richard D. Guyer, MD2; Jack E. Zigler, MD1; Donna D. Ohnmeiss, PhD3
1Texas Back Institute, Plano, TX, US; 2Center for Disc Replacement at Texas Back Institute, Plano, TX, US; 3Plano, TX, US
FDA Device/Drug Status: This abstract does not discuss or include any applicable devices or drugs.
115. Clinical outcomes of a PEEK-on-ceramic total disc replacement: data from three sites participating in the single-level cervical FDA IDE trial
Richard D. Guyer, MD1; Pierce D. Nunley, MD2; Domagoj Coric, MD3; Donna D. Ohnmeiss, PhD4
1Center for Disc Replacement at Texas Back Institute, Plano, TX, US; 2Spine Institute of Louisiana, Shreveport, LA, US; 3Carolina Neurosurgery & Spine Associates, Charlotte, NC, US; 4Plano, TX, US
FDA Device/Drug Status: Simplify Disc (Investigational/Not approved)
Discussion
116. Comparison of imputation methods for evaluating long term clinical outcomes following lumbar total disc replacement
Vikas V. Patel, MD1; Andrea Vovk2
1University of Colorado School of Medicine, Aurora, CO, US; 2Center Valley, PA, US
FDA Device/Drug Status: This abstract does not discuss or include any applicable devices or drugs.
117. Ten-year BRYAN cervical disc arthroplasty: does change in angular motion have an effect on changes in patient reported outcomes?
Swamy Kurra, MD1; K. Daniel Riew, MD2; Allan D. Levi, MD, PhD, FRCSC3; Jeffrey E. Florman, MD4; Travis Loidolt, DO, MBA5; William F. Lavelle, MD6
1Syracuse, NY, US; 2The Spine Hospital/Columbia Doctors/NewYork-Presbyterian/The Allen Hospital, New York, NY, US; 3University of Miami, Dept of Neurosurgery, Miami, FL, US; 4Maine Medical Partners, Scarborough, ME, US; 5The Orthopedic Specialty Center, Roseville, CA, US; 6Upstate Orthopedics, East Syracuse, NY, US
FDA Device/Drug Status: BRYAN cervical disc (Approved for this indication)
118. Prospective animal study of five FDA-approved cervical artificial discs
Hoon Choi, MD, MS1; Jamie Baisden, MD, FACS1; Narayan Yoganandan, PhD2
1Medical College of Wisconsin, Milwaukee, WI, US; 2Milwaukee VA Medical Center, Milwaukee, WI, US
FDA Device/Drug Status: Medtronic Bryan (Approved for this indication), Medtronic Prestige LP (Approved for this indication), Centinel Spine ProDisc-C (Approved for this indication), Biomet Zimmer LDR Mobi-C (Approved for this indication), Globus Secure C (Approved for this indication)
119. Ten-year outcomes of one-and two-level cervical disc arthroplasty: results from a U.S. multi-center study
Kee D. Kim, MD1; Gregory A. Hoffman, MD2; Hyun W. Bae, MD3; Andy Redmond, MD4; Pierce D. Nunley, MD5; A. David Tahernia, MD6; Robert J. Jackson, MD, FACS7
1UC Davis School of Medicine, Sacramento, CA, US; 2Orthopaedics NorthEast, PC, Fort Wayne, IN, US; 3Spine Institute St. John's Health Center, Los Angeles, CA, US; 4Precision Spine Care, Tyler, TX, US; 5Spine Institute of Louisiana, Shreveport, LA, US; 6Desert Orthopaedic Center, Rancho Mirage, CA, US; 7Laguna Hills, CA, US
FDA Device/Drug Status: This abstract does not discuss or include any applicable devices or drugs.
120. Can hybrid constructs prevent adjacent segments degeneration?A long-term follow-up results
Shiu-Jau Chen, MD, PhD
Mackay Memorial Hospital, Taipei, Taiwan, Taipei City, Taiwan
FDA Device/Drug Status: HPS, paradigm (Approved for this indication)
Discussion